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Background: Recognition of different genetic variants underlying osteoporosis would make it possible to introduce
individual, symptomatic treatment as well as early prophylaxis of osteoporosis.
The aim of the study was to evaluate the frequency of the rs2275913 (−197G > A) polymorphism of the IL-17 gene
and assess the relation of this polymorphism with the clinical parameters of the osseous turnover and degree of
the postmenopausal osteoporosis.
Methods: The study included 800 women of postmenopausal (505) and reproductive (295) ages throughout the
Wielkopolska region in Poland. The postmenopausal group included women with osteoporosis and osteopenia, and
those who were healthy. Women at reproductive age were healthy. The frequency of the tested gene
polymorphism was evaluated in the group where bone mineral density (BMD) was marked and in the control
group.
Results: The results obtained showed that the T-score in the female population with osteopenia was remarkably
lower in women showing the GG genotype of -197G > A polymorphism of IL-17 gene compared to patients with
heterozygous GA genotype. It has been shown that the BMD value for L2–L4 YA in the evaluated female population
with osteoporosis is significantly higher in women with the GA genotype of -197G > A polymorphism of IL-17 gene
compared to women with the GG genotype (76.32% versus 59.93%, P <0.05). It has also been noted that the BMD
value for L2 to L4 AM in patients with the GG genotype was lower than in women with the AA genotype (69.73%
versus 80.88%, P <0.05).
Conclusions: It is suggested that the -197G > A polymorphism of the IL-17 gene may be considered as a genetic
factor of postmenopausal osteoporosis. This polymorphism can influence the bone mineral density and T-score
value in young women and postmenopausal women.
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Interleukin 17 (IL-17) is a proinflammatory cytokine.
The gene IL-17 is localized at the short arm of chromo-
some 6 in position 6p12, coding the 155-length protein
product of amino acids. Interleukin 17A was the first cyto-
kine of the IL-17 family to be discovered [1]. Interleukin
17E is produced mainly by Th2 cells, whereas IL-17A and
IL-17 F are produced by different types of cells, including* Correspondence: metabolizm.db@gmail.com
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unless otherwise stated.T, NK or neutrophils. Moreover, IL-17A shows its highest
expression in the Th17 cells, for which it appears as an
identification feature.
For some years now, IL-17 and cytokines involved in
Th17 lymphocyte production, including IL-23 and IL-21,
have been believed to play a significant role in the
pathogenesis of rheumatoid arthritis. Today it is known
that IL-17 produces not only Th17 lymphocytes but also
other types of cells, including macrophages, neutrophils
and mast cells [2]. Interleukin 17 shows pro-destructive
properties, stimulating also the epithelial, endothelial andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and connective tissue that degrades metalloproteinases.
Some later studies have shown that IL-17 is localized in
the upper part of the inflammatory cascade and stimulates
fibroblasts, synovial membrane cells and macrophages
to produce more proinflammatory cytokines. More-
over, IL-17 initiated the loss of proteoglycans and, in
chondrocytes, stimulates increases in the expression of
enzymes responsible for collagen degradation. Metallo-
proteinases produced in such processes are regulated
by the IL-17 in the presence of the cytokines. It is
thought that the IL-17 stimulates osteoblasts to synthesize
prostaglandin E2 and to express the gene of receptor acti-
vator of NF-κB (RANK), which induces osteoclastogene-
sis. In this way IL-17, is jointly responsible for bone
resorption, as with rheumatoid arthritis. More extensive
understanding of the mechanism of the effect of IL-17
upon bone and cartilage cells could help introduce new
methods of treatment of skeletal system diseases.
Th17 cells have a major role in autoimmune diseases
thorough their involvement in development and differ-
entiation of osteoblasts, and when enhanced by IL-23,
they secrete, among other things, IL-17A and IL-17 F
[3,4]. During the inflammatory process in rheumatoid
arthritis, the axis IL-23-IL-17 appears much more im-
portant than the loop IL-12–IFN-γ, while the inter-
action between IL-17 and IL-23 plays an important
role not only during the initial phase of inflammation,
but also throughout the destructive phase marked by
osteoclastogenesis [5,6]. In rheumatoid arthritis IL-23
concentrations correlate to articular fluid IL-17 concentra-
tion and serum IL-17 and TNF-α concentrations [7,8].
Interleukin 17 stimulates, among other things, the pro-
duction of chemokines, other proinflammatory cytokines
(for example, IL-6 or TNF-α), proangiogenic factors and
cytokines (for example, IL-8), and cartilage degrading me-
talloproteinases as well as important cytokines promoting
osteoclastogenesis that results in bone destruction. In
humans differentiation of auxiliary T lymphocytes into
Th17 cells depends importantly on IL-6, whereas pre-
serving a constant pool of cells, accomplished through
proliferation, is supported by IL-23 [9].
Erosion of the osseous tissue occurs through two routes:
from the marrow cavity side, effecting in periarticular
osteoporosis and formation of geodes, and from the joint
cavity, leading, as a result, to bone erosion. The major rea-
son for bone resorption is the excess of cytokines, which
promote the osteoclastogenesis that is induced through
RANKL, including IL-1β, TNF-α, IL-6, IL-7 or IL-17, and
this process is accompanied by a deficiency of cytokines
hampering such process (IFN-γ, IFN-α, IL-4) [10]. IL-17,
however, not only enhances the production of osteoclasts,
initiated by RANKL, but is also capable of inducing such
processes independently [11].Recent studies have shown that localized at the top of the
inflammatory cytokine cascade, IL-17 stimulates fibroblasts,
synoviocytes and macrophages to produce more proinflam-
matory cytokines. Moreover, IL-17 initiates a remarkable
loss of proteoglycans and stimulates chondrocytes to pro-
duce enzymes that intensify collagen breakdown. Results
suggest that IL-17 stimulates osteoblasts to synthesize
prostaglandin E2 and to express RANK, effecting osteo-
clastogenesis induction. IL-17 is probably responsible for
enhanced resorption of the osseous tissue. A detailed
recognition of such mechanisms is likely to allow for some
new therapeutic methods [12,13].
Therefore this study aimed to define the role of relation
of the evaluated gene to the process of postmenopausal
osteoporosis and bone density, as well as other individual
and clinical parameters. The objective was to assess fre-
quency of the rs2275913 (−197G > A) polymorphism of
the IL-17A gene coding interleukin 17 among postmeno-
pausal women. The subject of analysis will be the relation
of the evaluated genetic variant to the stage of osseous
changes, as well as relation to the osseous turnover pa-
rameters and assessment of the role of the tested genetic
polymorphism in etiopathogenesis of osteoporosis.
Methods
Patients
The study comprised a group of unrelated Caucasian
women inhabiting the region of Wielkopolska. Investi-
gations included 800 women of postmenopausal age
(505) and reproductive age (295). The postmenopausal
group included 314 women with osteoporosis, 110 with
osteopenia and 81 healthy individuals. Densitometric
measurements were performed to define the bone min-
eral density (BMD) as well as T-score, Z-score, and the
mean bone mineral density index as compared to the
mean value for young adult (YA) women and mean
bone mineral density as compared to the mean value for
a given age (AM, age matched). Additionally, body
weight and height were measured to calculate the body
mass index (BMI).
A detailed history of each patient was taken to gain
information on the diseases developed, medication
prescribed, age of first and last menstruation, number
of deliveries, and birth weight, as well as smoking
habits.
Those women in whom menopause occurred at least
a year ago; who did not receive therapies possibly influ-
encing the bone mass, including selective estrogen re-
ceptor modulators – SERM, calcitonin, biphosphonates,
heparin, steroids, thyroid hormones, antiepileptic drugs,
GnRH analogues; and who underwent no hormonal
replacement therapy (HRT) were qualified for genetic
tests. Patients who had undergone bilateral ovariectomy,
as well as those suffering from endocrine and metabolic
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renal disorders, autoimmunologic diseases, or connect-
ive tissue diseases, as the above could possibly influence
the bony mass, were excluded from the study. Addition-
ally, a group of Caucasian women at reproductive age
were examined (mean age: 27.5 ± 4.7).
The study was planned according to statement of
Human and Animal Rights. It has been approved by
the local Bioethical Committee in Poznan (no. 1415/03
(158/06)).
Bone mineral density (BMD) was measured at the lum-
bar vertebrae, from vertebra L2 through L4, employing
dual energy X-ray absorptiometry (DXA). Densitometric
tests were performed with the use of a LUNAR DPX 100
unit (by Lunar Corporation, Madison, WI, USA). BMD
scores were expressed as g/cm2 and presented as T-score
and Z-score indices, referring to mean BMD values for
a given age group. BMD scoring between one standard
deviation from the mean age referring to the peak bone
mass, measured by DXA method, was considered normal
(T score from +1 to −1).
Tests comprised the influence of the evaluated poly-
morphism upon T-score, Z-score, L2–L4 AM, L2–L4
YA, L2–L4 BMD, BMI as well as other clinical
parameters.
Analysis of rs2275913 polymorphism of gene IL-17A by
real-time PCR
Genetic analysis was performed in the Laboratory of
Experimental Pharmacogenetics, at the Department of
Clinical Pharmacy and Biopharmacy, Poznan University of
Medical Sciences, Poland. DNA was isolated from periph-
eral blood leukocytes using a QIAamp DNA Blood Mini
Kit (Qiagen, USA). Analysis of the -197G > A polymorph-
ism of the IL-17A gene was performed with the real-time
PCR method with the use of LightCycler™ 480 system.
Genotypes were determined using HybProbe probes
(TiBMolbiol, Poland), which hybridize on the PCR
product and emit a fluorescent signal (FRET- fluores-
cence resonance energy transfer). Genotyping of the
rs2275913 (−197G > A) polymorphism was based on
melting curve analysis. LightSNiP set with phials con-
taining proper concentration of starters and probesTable 1 The frequency of genotypes of the -197G > A IL-17 po
osteoporosis (with osteopenia and healthy)
Genotype
IL-17
Women with osteoporosis Women
Observed value n (%) Expected value (%) Observe
GG 120 (39.2) 39.2 57 (36.1)
GA 143 (46.7) 46.8 73 (46.2)
AA 43 (14.1) 14.0 28 (17.7)
Total 306 (100) 100 158 (100specific for the amplified fragment, was used to deter-
mine the rs2275913 (−197G > A) polymorphism of the
IL-17A gene. Preparation of the LightSNiP set used for
real-time PCR was according to the manufacturers’
instructions. PCR cycling reactions consisted of initial
denaturation at 95°C (5 min), and 40 cycles with de-
naturation (15 s at 95°C), annealing (15 s, 60°C), and
extension (15 s at 72°C). Each 96-well plate contained
a mixture of case and negative control DNA samples.
Statistical analysis
Genotype and allele frequencies were calculated for
the -197G > A polymorphism and subsequently tested
for Hardy–Weinberg equilibrium with the Chi-square
test. Cross tables were constructed in order to compare
genotypes and allele frequencies between the study
population and controls. Odds ratios (OR) and the 95%
confidence interval (CI) were calculated. The statistical
significance of difference between control and experi-
mental groups was assessed by SPSS 17.0 software
using one-way ANOVA test (SPSS Inc.). The values of
P <0.05 were considered as a statistically significant
difference.
Results
Analysis of the frequency of the GG, GA and AA ge-
notypes of the -197G > A polymorphism of the IL-17
gene showed comparable results in groups with osteo-
porosis and without osteoporosis (osteopenic patients
and healthy postmenopausal women) (Table 1). No
statistically significant differences were noted. In both
groups, the heterozygous GA genotype was the most
frequently observed.
In women with osteopenia, the frequency of homozy-
gous GG and AA genotypes and the heterozygous GA
variant of the -197G > A polymorphism was comparable
to healthy postmenopausal women. No statistically signifi-
cant differences between the groups were noted (Table 2).
In both groups, the heterozygous GA genotype was the
most frequently observed.
Additionally, analysis of frequency of the GG, GA and
AA genotypes -197G >A polymorphism of the IL-17 gene
showed comparable results between the study groupslymorphism in women with osteoporosis and without
without osteoporosis OR 95% CI P
d value n (%) Expected value (%)
35.0 1.25 0.83 to 1.90 0.15
48.3 1.02 0.68 to 1.02 0.49
16.7 0.76 0.43 to 1.33 0.18
) 100 - - -




Women with osteopenia Women without osteoporosis OR 95% CI P
Observed value n (%) Expected value (%) Observed value n (%) Expected value (%)
GG 35 (35.0) 34.8 22 (37.9) 35.4 0.88 0.43 to 1.82 0.42
GA 48 (48.0) 48.4 25 (43.1) 48.2 1.22 0.60 to 2.47 0.33
AA 17 (17.0) 16.8 11 (19.0) 16.4 0.87 0.35 to 2.25 0.46
Total 100 (100) 100 58 (100) 100 - - -
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(GG = 35%, GA = 48%, AA = 17%) and healthy women
of reproductive age (GG = 37.9%, GA = 43.1%, AA = 19%).
In both groups, the heterozygous GA genotype was the
most frequent (Table 3).
Moreover, results presented in Tables 4 and 5 showed
that the T-score values were significantly lower in
women with the GG genotype of the -197G > A poly-
morphism of the gene IL-17 compared to patients with
the heterozygous GA genotype. As illustrated in Table 6,
the BMD value for the L2 to L4 YA in the female popu-
lation with osteoporosis was significantly higher in
women with the GA genotype compared to women with
the GG genotype (76.32% versus 59.93%, P <0.05). The
findings also showed that the BMD value for the L2 to
the L4 AM in patients with the GG genotype was lower
than in women with the AA genotype (69.73% versus
80.88%, p <0.05).
Discussion
The present study showed no significant changes related
to the impact of the examined IL-17 polymorphism on
the development of osteoporosis. However, a tendency
of this cytokine to influence the inhibition of osteopor-
osis in individuals with the homozygous AA genotype
was observed. Hence, it is suggested that the role of
IL-17 in bone economy may be manifested as a nega-
tive effect. Interleukin 17 is a cytokine associated with
some proinflammatory properties, and it is produced
by the T cell group, known as the Th17 cells [14-16].
Th17 cells were first identified in animal models of
autoimmune diseases [17]. Although Th17 cells haveTable 3 The frequency of genotypes of the -197G > A IL-17 po
or healthy and of reproductive age
Genotype
IL-17
Women with osteoporosis and osteopenia Women
Observed value n (%) Expected value (%) Observe
GG 155 (38.2) 38.1 98 (34.6)
GA 191 (47.0) 47.2 141 (49.8
AA 60 (14.8) 14.7 44 (15.5)
Total 406 (100) 100 283 (100been well characterized in animal models, their pres-
ence in humans is currently recognized. The recent
study attempted an evaluation of the potential role of
IL-17 as a mediator of bone remodeling, including
osteoclastogenesis.
Some centers have focused on the potential role of
IL-17 in joint damages. Koshy et al. [18] investigated
the ability of IL-17 to induce collagen release from the
cartilage. It was shown that the cytokine stimulated the
release of proteoglycans and type II collagen from
the bovine nasal cartilage, depending on the dose. Such
information indicates that IL-17 may act as the medi-
ator of the cartilage collagen breakdown. Another cen-
ter investigated the influence of exogenous IL-17 on
production and release of metalloproteinase-1 through
synoviocytes isolated from the synovial membrane
[19]. The exogenic addition of IL-17 effected a fivefold
increase in MMP-1 production by the synoviocyte
culture. The same experiment performed with the syn-
ovial membrane specimens instead of the synoviocyte
culture, showed that the exogenic addition of IL-17
had no remarkable influence upon MMP-1 production,
which emphasized the complex cooperation of several
types of cells within the synovial membrane. Sato et al.
[6] evaluated the role of the Th17 cells in osteoclasto-
genesis in mice arthritis. In such a model, the loss of
osseous tissue was associated with excessive bone
resorption by osteoclasts; in the presence of Th17 cells,
however, the osteoclasts were recreated. To solve
whether Th17 cells themselves or their products,
including IL-17, had a role in osteoclastogenesis, they
introduced Th17 cells from mice with no IL-17 to thelymorphism in women with osteoporosis and osteopenia
without osteoporosis OR 95% CI P
d value n (%) Expected value (%)
35.4 1.17 0.84 to 1.62 0.19
) 48.2 0.89 0.65 to 1.22 0.26
16.4 0.94 0.61 to 1.47 0.43
) 100 - - -
Table 4 Comparison of clinical parameters analyzed and particular genotypes of the -197G > A IL-17 polymorphism in
healthy women after menopause
Parameter/genotype GG GA AA
T-score −0.19 ± 0.49 −0.01 ± 0.72 0.32 ± 0.47
Z-score 0.60 ± 0.93 0.63 ± 0.87 0.70 ± 0.72
Body mass (kg) 70.33 ± 9.80 67.07 ± 9.81 67.13 ± 8.56
Height (cm) 163.04 ± 5.66 163.58 ± 6.02 163.97 ± 5.92
Body mass index (kg/m2) 25.07 ± 4.07 25.73 ± 3.80 25.10 ± 4.40
Age 52.03 ± 7.60 50.32 ± 8.02 54.68 ± 7.90
Birth weight 3552.83 ± 517.35 3506.79 ± 440.31 3708.44 ± 501.71
Reproductive years 36.63 ± 5.06 36.04 ± 4.72 35.36 ± 4.77
Age of menarche 12.78 ± 1.68 13.92 ± 1.69 13.83 ± 1.88
Last menstrual period age 50.17 ± 4.58 52.16 ± 4.04 51.03 ± 5.03
Number of pregnancies 2.10 ± 1.06 2.06 ± 1.50 1.87 ± 1.26
Years after menopause 7.45 ± 6.06 7.58 ± 5.47 7.90 ± 6.15
BMD L2–L4 (g/cm2) 1.14 ± 0.09 1.26 ± 0.15 1.24 ± 0.11
BMD L2–L4 YA (%) 93.45 ± 8.57 99.52 ± 8.06 106.24 ± 7.52
BMD L2–L4 AM (%) 100.02 ± 9.12 106.30 ± 10.02 109.56 ± 9.52
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genesis was observed, which pointed to the necessary
role of IL-17 in the osteoclastogenic processes. Never-
theless, IL-17 promoted osteoclasts in the co-breeding
system, which indicated that this cytokine did not
affect directly the osteoclast precursors but rather cells
that enhance osteoclastogenesis, that is, osteoblasts.
The exogenic addition of the IL-17 induced RANKLTable 5 Comparison of clinical parameters analyzed and part
women with osteopenia
Parameter/genotype GG
T-score* −2.03 ± 0.31
Z-score −0.90 ± 0.70
Body mass (kg) 63.35 ± 9.73
Height (cm) 163.15 ± 5.17
Body mass index (kg/m2) 25.01 ± 3.66
Age 56.15 ± 8.80
Birth weight 3206.52 ± 523.21
Reproductive years 35.36 ± 5.09
Age of menarche 14.13 ± 1.42
Last menstrual period age 51.50 ± 4.76
Number of pregnancies 1.89 ± 1.37
Years after menopause 7.04 ± 6.44
BMD L2–L4 (g/cm2) 0.95 ± 0.09
BMD L2–L4 YA (%) 77.84 ± 6.15
BMD L2–L4 AM (%) 92.44 ± 6.82
*P < 0.05 – significance of bold entries was observed by post hoc analysis.expression on the osteoblast surface, in this way facili-
tating osteoclastogenesis. The potential role of the Th17
cells in the pathogenesis of autoimmunologic rheumatoid
arthritis has also been investigated [20]. Arthritic joints
actively transcribed IL-17, which was not the case in non-
arthritic ones. Mice showing an IL-17 deficiency were
resistant to autoimmunologic arthritis, whereas interferon
γ deficiency resulted in the disease progression.icular genotypes of the -197G > A IL-17 polymorphism in
GA AA
−1.68 ± 0.50 −1.80 ± 0.41
−0.70 ± 0.71 −0.88 ± 0.66
65.02 ± 9.04 67.13 ± 8.52
160.38 ± 4.73 162.02 ± 5.71
23.60 ± 3.92 24.18 ± 4.15
50.73 ± 7.50 52.64 ± 8.06
3178.24 ± 477.32 3403.06 ± 501.76
35.03 ± 4.73 38.46 ± 4.36
12.83 ± 2.11 13.0 ± 1.82
49.02 ± 4.32 50.07 ± 1.53
1.92 ± 1.37 1.87 ± 1.53
7.58 ± 6.02 7.63 ± 5.74
1.01 ± 0.15 0.98 ± 0.12
86.06 ± 6.74 80.52 ± 5.13
90.07 ± 5.70 88.36 ± 6.24
Table 6 Comparison of clinical parameters analyzed and particular genotypes of the -197G > A IL-17 polymorphism in
women with osteoporosis
Parameter/genotype GG GA AA
T-score −2.93 ± 0.73 −3.30 ± 0.67 −2.97 ± 0.75
Z-score −1.50 ± 0.66 −1.62 ± 0.50 −1.40 ± 0.72
Body mass (kg) 64.11 ± 8.13 60.07 ± 9.22 59.68 ± 8.47
Height (cm) 163.61 ± 4.89 160.77 ± 4.90 157.82 ± 5.13
Body mass index (kg/m2) 25.92 ± 3.62 23.30 ± 4.11 22.61 ± 3.73
Age 60.07 ± 7.90 50.32 ± 8.18 52.13 ± 8.36
Birth weight 3192.68 ± 493.06 3062.23 ± 443.24 2878.24 ± 506.06
Reproductive years 37.28 ± 4.88 35.62 ± 5.39 34.02 ± 4.93
Age of menarche 13.68 ± 1.52 13.59 ± 1.84 12.87 ± 1.97
Last menstrual period age* 47.6 ± 4.82 50.78 ± 5.00 50.32 ± 4.36
Number of pregnancies 1.95 ± 1.09 1.93 ± 1.14 1.99 ± 1.31
Years after menopause* 10.31 ± 5.78 12.37 ± 6.33 12.85 ± 6.04
BMD L2–L4 (g/cm2) 0.84 ± 0.06 0.084 ± 0.04 0.082 ± 0.06
BMD L2–L4 YA (%)* 59.93 ± 6.02 76.32 ± 6.90 70.23 ± 6.93
BMD L2–L4 AM (%)* 69.73 ± 6.82 74.56 ± 6.14 80.88 ± 7.33
*P < 0.05 – significance of bold entries was observed by post hoc analysis.
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kines involved in the production of Th17 lymphocytes,
among other IL-23 and IL-21, have an important role in
the pathogenesis of rheumatoid arthritis. Today it is
known that interleukin 17 is produced not only by the
Th17 lymphocytes but also other cell types, including
macrophages, neutrophils and mast cells [2]. Interleukin
17 shows strong pro-destructive properties. It stimulates
the epithelial, endothelial and fibroblastic cells to release
proinflammatory cytokines and connective tissue degrad-
ing metalloproteinases [21,22]. Mice in which the IL-17
was neutralized or in which the expression was stopped
by means of genetic engineering showed a milder course
of bone and joint disease. Therefore, clinical studies
are being performed to use antibodies neutralizing this
cytokine [2].
Patients suffering from joint and bone disorders show
enhanced osteoclastogenesis and activity of osteoclasts
along with impaired bone remodeling [23]. It is known
that osseous tissue erosion follows two routes: from the
marrow cavity, effecting in osteoporosis, and from the
joint cavity, leading to bone erosion. In normal conditions,
RANKL occurs in osteoblasts, whereas under pathological
conditions, the sources are other cells. The major reason
for bone resorption is the excess of cytokines (including
IL-17), promoting osteoclastogenesis through RANKL
induction, accompanied by deficiency of cytokines ham-
pering such process [10]. On the other hand, IL-17 not
only enhances production of osteoclasts, as initiated by
RANKL, but is also capable of inducing such process
independently [11].Conclusions
Our results suggest that the -197G > A polymorphism of
the IL-17 gene may be considered as a genetic factor of
postmenopausal osteoporosis. This polymorphism can
have the influence on bone mineral density and T-score
value in young women and postmenopausal women.
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